I like your thinking, Bravo! One caveat - while the vaccine work with covid is "late" (thanks, BARDA), the process they used to develop the vaccine is where the real long term value is IMO. If this works, and I believe China will be well ahead of the FDA on proving it does work, NGIO will have a roadmap that can be used for other similar viruses (swine, bird, etc that we're all pretty sure will come back, if they ever really went away). That makes this work extremely valuable for the future; and as a bonus, if it is as targeted as Joe says, then it will become the "go to" vaccine when all the booster shot requirements from J&J, Mod, and Pzr come due.
Who wants all those free radicals in your system if you can use a target vaccine that also will likely have long term memory, so maybe you only need a booster every 5 - 7 years? Well, of course, J&J, Mod, Pzr want that, since we'll probably all be paying for those shots the next time around, but if NGIO does some smart advertising and education, maybe the market share of the big three will get eroded over time.
All the other initiatives are quite exciting as well. Keeping fingers crossed that this time, something doesn't conspire to limit GNBT/NGIO's potential.
(6)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links